Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 By Ogkologos - July 1, 2025 527 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KOMET study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Patient Guide on Bone Health in Cancer Now Available Also in French January 19, 2026 COVID-19 Is Decimating Nursing Homes, So GreaterGood Has Donated Masks To... May 8, 2020 Biomarkers of Pro-Inflammatory Response May Identifiy Cancer Patients at Risk of... November 21, 2020 Conducting Phase I Clinical Trials During the COVID-19 Pandemic August 5, 2020 Load more HOT NEWS New “Microwave Mammography” Promises to be Safer, More Accurate, and Pain-Free We’re asking scientists to tackle 9 of the toughest challenges in... Olaparib after Initial Treatment Delays Ovarian Cancer Progression EMA Recommends Extension of Therapeutic Indications for Tremelimumab
